Will advanced cholangiocarcinoma become a targetable malignancy?

Sarkis, Yara; Soueidy, Amine Al; Kourié, Hampig Raphaël

doi:10.1016/j.critrevonc.2021.103233

Cited by 5 publications

(2 citation statements)

References 59 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previously, cholangiocarcinoma was mainly treated with surgery and liver transplantation [ 12 ]. However, patients with cholangiocarcinoma have been generally in the late stage when clinically diagnosed, so the prognosis remains poor despite effective lesion clearance, and the condition of disease cannot be effectively relieved by postoperative radiotherapy and chemotherapy [ 13 ]. After transfection, oncogenes significantly increase the activity of angiogenesis by raising the VEGF expression, while neovascularization plays an important role in tumor growth, invasion, and metastasis [ 14 ].…”

Section: Discussionmentioning

confidence: 99%

Treatment of cholangiocarcinoma by pGCsiRNA-vascular endothelial growth factor in vivo

Lu,

2024

Asian Biomedicine

View full text Add to dashboard Cite

Background The early diagnosis and treatment of cholangiocarcinoma may benefit from specific tumor markers to be used in clinical practice. Objectives To investigate whether the pGCsiRNA-vascular endothelial growth factor (VEGF) can affect the onset and progression of cholangiocarcinoma and its possible mechanism using the targeted therapy of nude mouse model of cholangiocarcinoma with attenuated Salmonella carrying the plasmid pGCsiRNA-VEGF. Methods The nude mouse model of cholangiocarcinoma was established by tail vein injection of QBC939 cells and given attenuated Salmonella carrying the plasmid pGCsiRNA-VEGF. One month later, the tumor volume of nude mice was observed, and the tumor growth curve was plotted. The harvested tumors were weighed and detected for tissue structural changes and cell death status by hematoxylin–eosin staining. The protein and mRNA expressions of VEGF, matrix metalloproteinase 2 (MMP2), and MMP9 were detected by Western blotting and PCR, respectively. Results The tumor volume and weight of the pGCsiRNA-VEGF group were significantly smaller than those of the mock and the si-scramble groups (P < 0.05). The expressions of VEGF, MMP2, and MMP9 at the transcriptional and translational levels were inhibited by pGCsiRNA-VEGF. PGCsiRNA-VEGF promoted tissue apoptosis and destroyed the tissue structure. Conclusions In vivo silencing of VEGF can affect cell survival and inhibit cell migration, invasion, and development, probably by enhancing apoptosis and inhibiting the expressions of MMP2 and MMP9.

show abstract

Section: Discussionmentioning

confidence: 99%

Treatment of cholangiocarcinoma by pGCsiRNA-vascular endothelial growth factor in vivo

Lu,

2024

Asian Biomedicine

View full text Add to dashboard Cite

show abstract

“…Because EBDC patients are diagnosed at a later stage, we should pay more attention to patients with advanced EBDC, and the current progress in the treatment of advanced EBDC also indicates that everyone is aware of this problem [ 11 , 12 ]. Recent studies have shown that the liver is one of the most common distant single metastatic organs of EBDC [ 2 ].…”

Section: Introductionmentioning

confidence: 99%

Clinicopathological features, prognostic factors, and prognostic survival prediction in patients with extrahepatic bile duct cancer liver metastasis

Huang,

Chen,

Liu

et al. 2024

European Journal of Gastroenterology &Amp; Hepatology

View full text Add to dashboard Cite

Purpose Extrahepatic bile duct cancer (EBDC) is a compound malignant tumor mainly consisting of extrahepatic cholangiocarcinoma and gallbladder carcinoma. Most EBDC patients are diagnosed at an advanced stage characterized by distant metastases, and the liver is one of the common sites of metastasis. Hence, the purpose of this study is to investigate the clinicopathological features, identify prognostic risk factors, and assess the long-term prognosis of extrahepatic bile duct cancer liver metastasis (EBDCLM). Methods We identified 1922 eligible EBDCLM patients from the SEER database.Cox regression models were used to predict independent prognostic factors for overall survival (OS) and cancer-specific survival (CSS),and Kaplan–Meier survival curves were drawn. A nomogram was constructed based on the results of multivariate Cox analysis, and the predictive effect of the nomogram was evaluated. Results Age, surgery, chemotherapy, brain metastasis, and lung metastasis were common independent prognostic factors for OS and CSS, and radiotherapy and bone metastasis were independent prognostic factors for CSS. The Kaplan–Meier survival curves showed a significant increase in survival for patients aged less than or equal to 70 years, undergoing surgery and chemotherapy, and without lung metastases. The results showed that the nomogram constructed by us had good predictability and ha d strong clinical application value. Conclusion Our study identified age, surgery, chemotherapy, brain metastasis, and lung metastasis as independent prognostic factors for EBDCLM patients. The nomogram can accurately predict the survival probability, which is helpful for clinicians to assess the prognosis of patients with advanced EBDC and provide personalized clinical decisions.

show abstract